Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...

Full description

Bibliographic Details
Main Authors: Adnan Asif Parvez Ghias, Shahzeem Bhayani, David J. Gemmel, Sudershan K. Garg
Format: Article
Language:English
Published: Taylor & Francis Group 2018-03-01
Series:Journal of Community Hospital Internal Medicine Perspectives
Subjects:
Online Access:http://dx.doi.org/10.1080/20009666.2018.1454787
id doaj-1a3b2049ee3a4befb2f496b945886daf
record_format Article
spelling doaj-1a3b2049ee3a4befb2f496b945886daf2020-11-25T00:43:17ZengTaylor & Francis GroupJournal of Community Hospital Internal Medicine Perspectives2000-96662018-03-0182879110.1080/20009666.2018.14547871454787Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicityAdnan Asif Parvez Ghias0Shahzeem Bhayani1David J. Gemmel2Sudershan K. Garg3St. Elizabeth Health CenterSt. Elizabeth Health CenterSt. Elizabeth Health CenterHematology and Oncology, Mercy HealthGastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case discusses rapidly progressive dyspnea and heart failure in an elderly male with metastatic GIST who was started on imatinib. Although reported as a rare and sporadic side effect of imatinib, the current case illustrates rapidity and the clinical significance of cardiotoxicity, with onset at 2 weeks. Cases of imatinib-induced cardiotoxicity can range from being mild ventricular dysfunction to overt heart failure. Prior to starting imatinib, our patient had a history of hypertension. He subsequently ended up developing heart failure as acknowledged by the echocardiogram (ECHO). In general, elderly with preexisting cardiovascular comorbidity are at greater risk. The goal in such situations is immediate discontinuation or reduction of the imatinib dosage. The case prompts for awareness of imatinib cardiotoxicity. Moreover, a pretreatment cardiac assessment along with monitoring throughout therapy is therefore advisable. Also, imatinib-induced cardiotoxicity should be differentiated from imatinib-associated fluid retention, in which ECHO findings can be normal. This case report raises the concern for accelerated cardiotoxicity profile of imatinib. Further prospective studies with multidisciplinary input are needed to establish this association further.http://dx.doi.org/10.1080/20009666.2018.1454787Gastrointestinal stromal tumorsGISTsimatinibcardiac toxicityheart failurefluid retentionimatinib toxicityrareLV dysfunction
collection DOAJ
language English
format Article
sources DOAJ
author Adnan Asif Parvez Ghias
Shahzeem Bhayani
David J. Gemmel
Sudershan K. Garg
spellingShingle Adnan Asif Parvez Ghias
Shahzeem Bhayani
David J. Gemmel
Sudershan K. Garg
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Journal of Community Hospital Internal Medicine Perspectives
Gastrointestinal stromal tumors
GISTs
imatinib
cardiac toxicity
heart failure
fluid retention
imatinib toxicity
rare
LV dysfunction
author_facet Adnan Asif Parvez Ghias
Shahzeem Bhayani
David J. Gemmel
Sudershan K. Garg
author_sort Adnan Asif Parvez Ghias
title Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
title_short Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
title_full Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
title_fullStr Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
title_full_unstemmed Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
title_sort rapidly progressive dyspnea in gastrointestinal stromal tumor (gist) with imatinib cardiac toxicity
publisher Taylor & Francis Group
series Journal of Community Hospital Internal Medicine Perspectives
issn 2000-9666
publishDate 2018-03-01
description Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case discusses rapidly progressive dyspnea and heart failure in an elderly male with metastatic GIST who was started on imatinib. Although reported as a rare and sporadic side effect of imatinib, the current case illustrates rapidity and the clinical significance of cardiotoxicity, with onset at 2 weeks. Cases of imatinib-induced cardiotoxicity can range from being mild ventricular dysfunction to overt heart failure. Prior to starting imatinib, our patient had a history of hypertension. He subsequently ended up developing heart failure as acknowledged by the echocardiogram (ECHO). In general, elderly with preexisting cardiovascular comorbidity are at greater risk. The goal in such situations is immediate discontinuation or reduction of the imatinib dosage. The case prompts for awareness of imatinib cardiotoxicity. Moreover, a pretreatment cardiac assessment along with monitoring throughout therapy is therefore advisable. Also, imatinib-induced cardiotoxicity should be differentiated from imatinib-associated fluid retention, in which ECHO findings can be normal. This case report raises the concern for accelerated cardiotoxicity profile of imatinib. Further prospective studies with multidisciplinary input are needed to establish this association further.
topic Gastrointestinal stromal tumors
GISTs
imatinib
cardiac toxicity
heart failure
fluid retention
imatinib toxicity
rare
LV dysfunction
url http://dx.doi.org/10.1080/20009666.2018.1454787
work_keys_str_mv AT adnanasifparvezghias rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity
AT shahzeembhayani rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity
AT davidjgemmel rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity
AT sudershankgarg rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity
_version_ 1725279366534922240